Teva to acquire ratiopharm
This article was originally published in The Tan Sheet
Executive Summary
Teva Pharmaceutical Industries' nearly $5 billion (€3.6 billion) pending acquisition of Germany's second-largest generics manufacturer ratiopharm catapults the Israeli company to second place in Germany's generic market. The deal also gives Teva an OTC platform in Germany, which could help the firm gain favor with pharmacists. In Germany, firms can offer pharmacists incentives for choosing specific OTC products, but not for generics. Ratiopharm sells approximately 20 percent non-prescription drugs, including cold and flu remedies, plant-derived medicines and health supplements, according to its Web site. Teva expects the mostly cash deal to be accretive nine months after it closes
You may also be interested in...
P&G/Teva Joint Venture Lays Foundation For Switches, Product Launches
Procter & Gamble and Teva Pharmaceutical Industries combine their consumer businesses in a joint venture that creates a leading platform for Rx-to-OTC switches and new consumer health products.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.